Churchill and Seviora borrow $400 million against secondaries

Churchill and Seviora have put a $400 million collar around a portfolio of private equity secondaries, borrowing against the assets rather than selling them. Announced August 20, the financing lets Temasek-backed Seviora raise cash against its secondaries positions without taking a discounted bid in the open market. It is the clearest sign yet that the market's record capital overhang is pushing holders into structured finance instead of sales.

The $400 million collateralized fund obligation arrives in a market that is badly out of balance. Secondaries funds raised a record $93 billion in a year when total private equity fundraising fell for the second straight year. The capital has not spread evenly. Buyers have concentrated at the quality end, compressing discounts for the portfolios everyone wants; more complicated or older assets still trade at wider marks. In that environment, a manager who believes the portfolio is worth more than the clearing price has a third option: borrow.

A CFO works like this. The manager pledges the underlying fund interests as collateral and receives a loan sized to a conservative advance rate against the portfolio's net asset value. The manager keeps the upside, keeps the management fees, and avoids crystallizing a loss by selling. The lender gets a spread above its financing cost and a claim on a diversified pool of assets. Churchill, the lender here, has taken the credit risk. Seviora kept the portfolio.

The arithmetic is not uniform. A CFO works best when three things line up: the portfolio is diversified across enough underlying funds to satisfy lenders, the advance rate leaves enough cushion for the lender, and the manager's cost of debt is lower than the secondaries market's demanded discount. Those conditions are not universal. For most holders, a sale remains simpler. But for a manager with high-quality secondaries interests inside a Temasek-backed balance sheet, they are closer than they have been.

The parallel with GP-led continuation vehicles is direct. A continuation vehicle also lets a sponsor hold an asset longer, but only by moving the asset into a new fund with new investors and often new economics. A CFO gets the same hold with debt and leaves the existing fund structure intact. For managers whose limited partners want liquidity but not a fire sale, the loan can be cheaper than the legal and placement costs of a continuation vehicle. It also does not require striking a new set of valuations at the bid.

The secondaries market has become a magnet for fresh capital. Continuim's third fund took 32 days to raise. It closed at $548 million. HarbourVest Partners and UC Investments closed a $1 billion mandate. These are not one-off events. They are part of a larger flow of institutional money into a strategy that promises faster realization than primary private equity and less J-curve drag. That appeal has drawn record fundraising, which is now reshaping what a sale even means for a motivated holder.

Continuim's 32-day close is the demand side in miniature. Raising $548 million in just over a month tells sellers that capital is not scarce. The message to lenders is that the secondaries market's own funds now have dry powder that could instead be deployed as debt against the same assets. A CFO competes not just with continuation vehicles but with the secondaries buyer's own balance sheet.

Ardian's co-CEO has said infrastructure secondaries are drawing new entrants, framing that fresh capital as a mispricing opportunity. Infrastructure secondaries had been a specialist corner. Now generalist secondaries buyers and new platforms are bidding for the same assets. When more capital chases a finite set of high-quality infrastructure funds, the entry discount shrinks. For a seller, that compression is good. For a buyer, it demands better sourcing or a different structure. For a manager like Seviora, it makes borrowing against the portfolio a rational arbitrage against the bid.

The SEC's opening valuation requests add another layer. The regulator has begun naming funds in initial valuation inquiries. For secondary buyers, marks become moving targets. A portfolio that carried a 20% discount to net asset value in March may be repriced by the time a deal closes. The assets haven't changed; the seller's marks were adjusted under scrutiny. In such a market, a debt provider using conservative advance rates may be more comfortable than an equity buyer betting on a discount. The lender does not need the portfolio to appreciate; it needs the assets to cover the loan.

NAV financing has competed with secondaries buyers before, but the size and the sponsor matter. A $400 million CFO backed by private equity secondaries is large enough to be a real alternative for a mid-sized manager. Temasek's backing gives Seviora a long-duration horizon; it can afford to wait for the assets to pay out rather than accept a bid. Churchill gets a structured credit asset with a defined claim, not an equity position in a hard-to-value fund. The alignment is plain.

The risk sits in the collateral. A CFO is only as good as the underlying funds' cash flows. If the secondaries portfolios hold tail-end assets with uncertain distributions, the advance rate will reflect that. If the assets are concentrated in a few managers, diversification is thinner than the structure suggests. The fact that the deal got done at $400 million suggests the collateral was acceptable. It also shows why lenders like Churchill are selective. No broad market shift yet, but a window into how the most sophisticated holders are solving a liquidity problem.

The Churchill-Seviora deal may set a precedent for other Temasek-affiliated managers and for the broader universe of secondaries holders. If a $400 million CFO can be placed against a secondaries portfolio, the next one will be measured against it. The cost of debt, the advance rate, and the legal terms will become the reference points. In a market where secondaries buyers have already pushed pricing to record levels, sellers now have a live benchmark for not selling.

The secondaries market spent a decade building a bid. The next decade may be about deciding when not to take it.